Relay Therapeutics Stock Current Valuation
| RLAY Stock | USD 3.06 0.19 5.85% |
Valuation analysis of Relay Therapeutics helps investors to measure Relay Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Relay Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Relay Therapeutics is based on 3 months time horizon. Increasing Relay Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Relay Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Relay Stock. However, Relay Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.06 | Real 2.96 | Hype 3.06 | Naive 2.99 |
The intrinsic value of Relay Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Relay Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Relay Therapeutics helps investors to forecast how Relay stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Relay Therapeutics more accurately as focusing exclusively on Relay Therapeutics' fundamentals will not take into account other important factors: Relay Therapeutics Company Current Valuation Analysis
Relay Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Relay Therapeutics Current Valuation | (213.24 M) |
Most of Relay Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Relay Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Relay Therapeutics has a Current Valuation of (213.24 Million). This is 101.48% lower than that of the Biotechnology sector and 104.59% lower than that of the Health Care industry. The current valuation for all United States stocks is 101.28% higher than that of the company.
Relay Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Relay Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Relay Therapeutics could also be used in its relative valuation, which is a method of valuing Relay Therapeutics by comparing valuation metrics of similar companies.Relay Therapeutics is currently under evaluation in current valuation category among its peers.
Relay Fundamentals
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (38.54) % | ||||
| Current Valuation | (213.24 M) | ||||
| Shares Outstanding | 169.52 M | ||||
| Shares Owned By Insiders | 1.79 % | ||||
| Shares Owned By Institutions | 99.34 % | ||||
| Number Of Shares Shorted | 15.79 M | ||||
| Price To Book | 0.67 X | ||||
| Price To Sales | 54.97 X | ||||
| Revenue | 10.01 M | ||||
| Gross Profit | (305.43 M) | ||||
| EBITDA | (380.21 M) | ||||
| Net Income | (337.71 M) | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 8.72 X | ||||
| Total Debt | 48.5 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 15.22 X | ||||
| Book Value Per Share | 4.64 X | ||||
| Cash Flow From Operations | (249.11 M) | ||||
| Short Ratio | 10.69 X | ||||
| Earnings Per Share | (2.23) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 19.64 | ||||
| Number Of Employees | 261 | ||||
| Beta | 1.65 | ||||
| Market Capitalization | 550.05 M | ||||
| Total Asset | 871.3 M | ||||
| Retained Earnings | (1.74 B) | ||||
| Working Capital | 758.48 M | ||||
| Net Asset | 871.3 M |
About Relay Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Relay Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relay Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relay Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.